Twice-nightly treatment for narcolepsy or idiopathic hypersomnia
Part of Brain & nervous system, Mental health clinical trials.
This study tests whether taking the sleep medicine Xywav two times each night is safe and helps control symptoms better than a placebo. People with narcolepsy or idiopathic hypersomnia may join, including those who have not tried oxybate medicines before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with narcolepsy (type 1 or 2) or idiopathic hypersomnia (IH)
- For narcolepsy type 1, have had at least 14 cataplexy attacks (sudden muscle weakness) in a typical two-week period
- For IH, sleep at least 7 hours per night on average
- Either currently taking a stable dose of an oxybate medicine for at least 2 months, or have significant daytime sleepiness (Epworth score > 11) if not on oxybate
- Must be able to stop certain other medicines (like alerting agents or anticataplectics) during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called ORX750 for people with narcolepsy or idiopathic hypersomnia. You would need to stop your current sleepiness medicines to see if ORX750 helps reduce daytime sleepiness.
This study tests a new medicine, HBS-301, for people with narcolepsy type 1 or type 2 who still have excessive daytime sleepiness. If you take other medications for sleepiness or mood, they must be stable for at least 3 months, and you cannot take some as-needed sleepiness medicines.
This study continues treatment with the investigational drug ALKS 2680 for people who have already completed a previous ALKS 2680 study for narcolepsy or idiopathic hypersomnia. It aims to see how safe and effective the drug is over a longer period.
This trial tests whether low-dose sodium oxybate can improve symptoms in adults with idiopathic hypersomnia, a condition that causes excessive sleepiness. You’d likely be asked to pause this standard treatment briefly while baseline testing is completed, and you’d use reliable contraception during and after the study drug.
This study tests a new drug called E2086 to see if it can help reduce daytime sleepiness and sudden muscle weakness in adults with narcolepsy. It involves two groups: people with cataplexy (type 1) and those without (type 2).
This study tests whether low sodium oxybate, a medication that improves alertness, can help reduce symptoms like dizziness and fatigue in people who have both idiopathic hypersomnia and POTS. You would stay on your current daytime medications, but some heart-related drugs may be paused temporarily before tests.
Hear when a new Narcolepsy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.